NCT07416240

Exploratory Clinical Study of Claudin18.2-Targeted Activated DC and CAR-T Therapy in Advanced Pancreatic Cancer.

Exploratory Clinical Study of Combined Claudin18.2-Targeted Activated DC and CAR-T Therapy in Patients With Advanced Pancreatic Cancer

• Status: Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Hainan Cancer Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, single-arm clinical study designed to evaluate the safety and preliminary efficacy of Claudin18.2 Targeted Activated DC combined with CAR-T therapy in patients with Advanced Pancreatic Cancer. This combination therapy activates dendritic cells (DCs) to precisely target the tumor site, reshaping the tumor immune microenvironment, breaking down the immunosuppressive barrier, and allowing CAR-T cells to penetrate deeper into the tumor more efficiently, precisely and persistently killing cancer cells.

Conditions

• Advanced Pancreatic Cancer

Interventions

Type	Name	Description
BIOLOGICAL	Claudin18.2 Targeted Activated Dendritic Cells	Autologous dendritic cells (DCs) genetically modified to express Claudin18.2 chimeric antigen receptor (CAR) and activation domain
BIOLOGICAL	Claudin18.2 Targeted CAR-T Cells	Autologous T cells genetically modified to express Claudin18.2 chimeric antigen receptor (CAR)

Timeline

• Start date: 2026-02-18
• Primary completion: 2028-02-18
• Completion: 2028-08-18
• First posted: 2026-02-18
• Last updated: 2026-02-18

Locations

1 site across 1 country: China